Compare Mutual Funds
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹100
-
Expense Ratio
2.17
-
NAV
₹13.87
-
Fund Started
16 Jan 2024
-
Fund Size
₹556.42 Cr
-
Exit Load
Exit load of 1%, if redeemed within 1 months.
-
1 Year
9.21%
-
3 Year
-
-
5 Year
-
-
Equity
98.05%
-
Cash
-1.83%
-
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 12.35% |
JB Chemicals & Pharmaceuticals Ltd. | 8.90% |
Lupin Ltd. | 5.77% |
Divi's Laboratories Ltd. | 5.31% |
Apollo Hospitals Enterprise Ltd. | 4.24% |
Laurus Labs Ltd. | 3.93% |
Fortis Healthcare Ltd. | 3.85% |
Max Healthcare Institute Ltd. | 3.79% |
Glenmark Pharmaceuticals Ltd. | 3.17% |
Krishna Institute of Medical Sciences Ltd | 3.16% |
-
Name
-
-
Start Date
-
-
Description
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
-
Launch Date
16 Jan 2024
-
